New study seeks safer dosing of cancer drug for patients with liver issues

NCT ID NCT07036133

Recruiting now Disease control Sponsor: Acrotech Biopharma Inc. Source: ClinicalTrials.gov ↗

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This early-stage study tests the drug pralatrexate in 24 adults with advanced cancer and varying levels of liver function. The goal is to see how the body processes the drug and to find the right dose for people with mild, moderate, or severe liver impairment. Participants receive the drug weekly for six weeks, followed by a week off, while researchers monitor side effects and drug levels in the blood.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: pralatrexate
What this could lead to: If successful, this study could help doctors safely dose pralatrexate in cancer patients with liver problems, expanding treatment options.
What could go wrong: This is a very early, small Phase 1 trial focused on safety and dosing, not on curing cancer. The drug may not work well or could cause side effects, especially in those with severe liver impairment.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hematopoietic and lymphoid system neoplasm neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS HEMATOLOGIC MALIGNANCIES

Contacts and locations

Locations

Gabrail Cancer Center
RECRUITING

Canton, Ohio, 44718, United States
Karmanos Cancer Institute
RECRUITING

Detroit, Michigan, 48201, United States
Northwestern University - Feinberg School of Medicine
RECRUITING

Chicago, Illinois, 60611, United States
TOI Clinical Research
WITHDRAWN

Cerritos, California, 90703, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.